Abstract
Chronic obstructive pulmonary disease (COPD) is an independent risk factor for osteoporosis. Oral glucocorticoids are deleterious to bone; however, the impact of inhaled glucocorticoids (ICS) remains unclear. Our objective was to determine whether ICS contribute to osteoporosis and fragility fractures. Sixty-one COPD patients, 35 current users of ICS and 26 who had never received glucocorticoids, were evaluated for bone mineral density (BMD) and body composition and underwent vertebral fracture assessment (VFA). The risk factors for bone disease considered for analysis were age, gender, ICS use, body mass index (BMI), muscle mass index (MMI), and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) category. The Fracture Risk Assessment Tool (FRAX) calculation tool for the Brazilian population was also employed. The groups did not differ regarding gender, BMI, MMI, GOLD class, lowest values of the BMD T-score and Z-score, prevalence of osteoporosis, or low BMD for age. Vertebral fractures were identified via VFA in seven patients using ICS and in none of those not receiving glucocorticoids (p = 0.02). There was a trend for an association between MMI and osteoporosis (p = 0.05) and for a progressive decrease in the BMD Z-score according to the COPD severity assessed via the GOLD score (p = 0.08). Vertebral fractures were not associated with osteoporosis (p = 0.69) or low MMI (p = 0.12). The fracture risk was not estimated by FRAX. ICS may lead to bone fragility before a significant decrease in BMD. Low muscle mass and COPD severity may contribute to bone disease.
Similar content being viewed by others
References
Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C et al (2013) Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347–365
Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of major effect. BMJ 315:841–846
Gan WQ, Man SF, Senthilselvan A, Sin DD (2004) Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59:574–580
Bolton CE, Ionescu AA, Shields KM, Pettit RJ, Edwards PH (2004) Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170:1286–1293
Jorgensen NR, Schwarz P, Holme L, Henriksen BM, Petersen LJ, Backer V (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross-sectional study. Respir Med 101:177–185
Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA (2009) Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 34:209–218
Maggi S, Siviero P, Gonnelli S, Schiraldi C, Malavolta N et al (2009) Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO Study. J Clin Densitom 12:345–352
Majumdar SR, Villa Roel C, Lyons KJ, Rowe BH (2010) Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir Med 104:260–266
Gonnelli S, Caffarelli C, Maggi S, Guglielmi G, Siviero P et al (2010) Effect of inhaled glucocorticoids and beta2 agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int 87:137–143
Watanabe R, Tanaka T, Aita K, Hagiya M, Homma T (2015) Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab 33:392–400
Dubois EF, Roder E, Dekhuijzen R, Zwinderman AE, Schweitzer DH (2002) Dual X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest 121:1456–1463
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. Osteoporos Int 25:2359–2381
Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS et al (2002) Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 19:1058–1063
Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E et al (2003) Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 14:179–190
Wilkie M, Finch S, Schembri S (2015) Inhaled corticosteroids for chronic obstructive pulmonary disease: the shifting treatment paradigm. COPD 12:582–590
Papaioannou A, Parkinson W, Ferko N, Probyn L, Ioannidis G et al (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 14:913–917
Schlaich C, Minne HW, Bruckner T, Wagner G, Gebest HJ et al (1998) Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 8:261–267
Carter JD, Patel S, Sultan FL, Thompson ZJ, Margaux H et al (2008) The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102:1165–1172
Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE et al (2001) Identification and fracture outcomes of undiagnosed low mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822
Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone (NY) 34:195–202
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328
Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995
Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML et al (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395
Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK et al (2004) Official positions of the International Society for clinical densitometry. J Clin Endocrinol Metab 89:3651–3655
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T et al (2010) Sarcopenia: European consensus on definition and diagnosis. Age Ageing 39:412–423
Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fracture in osteoporosis. J Bone Miner Res 11:984–996
Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS (1999) Declining bone mass in men with chronic obstructive pulmonary disease: contribution of glucocorticoids treatment, body mass index, and gonadal function. Chest 116:1616–1624
McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W et al (1998) Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:704–709
Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003537
Graat-Verboom L, Smeenk FW, van den Borne BE, Spruit MA, Jansen FH et al (2012) Progression of osteoporosis in patients with COPD: a 3-year follow-up study. Respir Med 106:861–870
Fergusson GT, Calverley MA, Anderson JA, Jenkins CR, Jones PW et al (2009) Prevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD Health Study. Chest 136:1457–1465
Pauwels RA, Lofdahl GC, Laitinen LA, Schouten JP, Postma DS et al (1999) Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340:1948–1953
De Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW (2005) Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 25:879–884
Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, Chatzimavridou-Grigoriadou V, Siasos G et al (2013) Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? Respirology 18:147–153
Elmståhl S, Ekström H, Johnell O, Gerhardsson de Verdier M, Norjavaara E (2006) No association between inhaled corticosteroids and whole body DXA in postmenopausal women. Pharmacoepidemiol Drug Saf 15:527–535
Loke YK, Cavallazzi R, Singh S (2011) Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66:699–708
Acknowledgements
The authors thank the Division of Pneumology at the Hospital Universitario Clementino Fraga Filho HUCFF-UFRJ for the collaboration.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Appendix
Appendix
See Table 5.
About this article
Cite this article
Gonçalves, P.A., dos Santos Neves, R., Neto, L.V. et al. Inhaled glucocorticoids are associated with vertebral fractures in COPD patients. J Bone Miner Metab 36, 454–461 (2018). https://doi.org/10.1007/s00774-017-0854-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-017-0854-3